# Adversarial verification verdict — sezary_syndrome.md (wave9)

Checked against: /Users/diwakarkumar/.claude/jobs/142278a7/tmp/devita.txt, DeVita Ch.68 "Cutaneous Lymphomas" (MF/SS treatment section, lines ~271600-272470: Table 68.6, Fig 68.2 algorithm, "Systemic Therapy for MF/SS" subsections on interferons/ECP/bexarotene/HDAC inhibitors/denileukin diftitox/monoclonal antibodies/cytotoxic chemo/allogeneic SCT).

## 1. DOSE LEAK
None. Grepped the sidecar for digits (`grep -n '[0-9]'`) — the only numeric hits are "T4" (a disease-stage label, not a dose) and prose references to "12th ed." No mg, mg/m2, AUC, Gy, or numbered schedule anywhere in the clinical body text.

## 2. UNGROUNDED CLAIMS
None rise to fabrication. Every specific drug/regimen/trial claim traces to the DeVita text:
- ECP + bexarotene/INF-alfa synergy, shortened time to response → matches "In most treatment centers, ECP is combined with bexarotene and/or INF-α" / "Immune adjuvant therapies combined with ECP have appeared to be synergistic and shortened the time to response" (Duvic et al.).
- ECP+TSEBT improved cause-specific survival in erythrodermic patients, retrospective → matches Wilson et al. data (explicitly "the data are retrospective").
- Bexarotene mechanism (CCR4/E-selectin downregulation), toxicities (lipids/cholesterol, thyroid suppression), combination with ECP → verbatim-supported.
- Mogamulizumab: anti-CCR4 mAb, higher ORR in SS vs skin-predominant MF, randomized vs vorinostat (MAVORIC), high blood-compartment clearance, now preferred for SS → directly supported, including "Mogamulizumab has now become a preferred treatment for SS patients."
- Romidepsin/vorinostat FDA-approved for CTCL → supported.
- Brentuximab vedotin: anti-CD30 ADC, FDA approval in CD30-expressing MF/CTCL (ALCANZA) → supported. Minor imprecision: sidecar's "CD30 expression status should inform its use" glosses over DeVita's note that response did NOT correlate with CD30 expression level in the earlier phase II trial; the ALCANZA-based FDA label restriction to CD30-expressing disease is still accurate and guideline-standard, so this is a defensible simplification, not a fabrication.
- Denileukin diftitox "less commonly [used]... given toxicity and availability considerations" → consistent with real-world market withdrawal, reasonable.
- Single-agent > multi-agent cytotoxic chemo preference, reserved for refractory/extensive disease → matches "single-agent therapies are preferred except in patients who are refractory or who present with extensive adenopathy and/or visceral involvement and require immediate palliation."
- Allogeneic HSCT as only potentially curative option, for younger/transplant-eligible/clinically-aggressive/exhausted-other-options patients, TSEBT incorporated into conditioning in some series → matches Fig 68.2 algorithm and the MD Anderson/Weng et al. series text almost point for point.
- Monitoring (imaging at staging + follow-up, BM biopsy in advanced disease/compromised hematologic function, watch for LCT and infection) → matches the staging/workup paragraph in the source.

Two sentences are synthesis rather than direct quotes (flagged for awareness, not blocking):
- "Standard phototherapy... is more relevant to patch/plaque MF than to the leukemic phenotype of SS" — reasonable inference from the treatment algorithm (Fig 68.2 routes SS/advanced disease through photopheresis, not UVB/PUVA) but not an explicit DeVita sentence.
- "monoclonal-antibody approaches... generally preferred over [denileukin diftitox/alemtuzumab] when disease burden is predominantly circulating" — reasonable given mogamulizumab's stated SS preference, but is the drafting agent's synthesis, not a direct DeVita statement.
Neither is contradicted by the source, both are uncontroversial given the surrounding grounded facts.

Appropriately excluded (per the sidecar's own disclosure and confirmed against source): IPH4012 (KIR3DL2-targeted antibody, spelled as in the source-extracted text) and duvelisib (PI3K inhibitor) — DeVita frames both as early-phase/investigational only ("a larger confirmatory trial is under way" / phase I/II, n=19), and the sidecar correctly keeps them out of the main body, naming them only in the omission footnote.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th ed." — name only, no page numbers. Correct format.

One line (line 13, topical corticosteroids/antipruritics) is explicitly self-flagged as "general oncology standard, not from DeVita's section on this disease" — transparent, not a citation violation.

## 4. VERDICT: CLEAN (ready for R1)

No dose leaks, no fabricated regimens/trials/statistics, citation line present and correctly scoped, investigational agents correctly excluded from the standard-of-care framing. The two synthesis sentences noted above are minor and non-blocking — R1 may tighten them to hedge language ("may be more relevant to...", "is often reserved for...") if it wants belt-and-suspenders precision, but they do not misrepresent the source.
